Knome, a Cambridge, MA-based genomics sequencing and analysis company, received $5 million from France’s bioMérieux in exchange for an equity stake. It’s part of a partnership deal in which the French company will use Knome’s technology to develop in vitro diagnostics for cancer and infectious diseases, the companies announced today. As part of the deal, bioMérieux will appoint its CEO Stéphane Bancel as a director on the Knome board. Ryan profiled Knome in January.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
